Primary source: Health Canada
Health Canada issued a recall for ARTIS Icono imaging systems due to potential safety or performance defects.
The defect may compromise patient or operator safety during imaging procedures.
Identify and quarantine affected ARTIS Icono systems in inventory; contact manufacturer for update guidance.
Regulatory Intelligence Lead
Single event
Contact the manufacturer or distributor for guidance on necessary software or hardware updates.
Identify and quarantine affected ARTIS Icono systems in inventory; contact manufacturer for update guidance.
Recall of ARTIS Icono Ceiling, Floor and Biplane Systems notified by Health Canada. The manufacturer or distributor should be contacted for guidance on necessary software or hardware updates.
What changed: Health Canada issued a recall for ARTIS Icono imaging systems due to potential safety or performance defects.
Why it matters: The defect may compromise patient or operator safety during imaging procedures.
Practical implication: Identify and quarantine affected ARTIS Icono systems in inventory; contact manufacturer for update guidance.
Published from the Firecrawl agent regulatory extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
